Max Chat
Calendrier des promotions Bionomics Limited
Calendrier avancé
Graphique simple
À propos de l'entreprise Bionomics Limited
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.Paramètres de base
IPO date
2021-12-16
ISIN
US09063M2052
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
aud
Сайт
Grade
Sous-estimation
| Nom | Signification | Grade |
| P/S | 4290.29 | 1 |
| P/BV | 4.91 | 3 |
| P/E | 0 | 0 |
Efficacité
| Nom | Signification | Grade |
| ROA | -66284.99 | 0 |
| ROE | -117366.73 | 0 |
| ROIC | 0 | 0 |
Dividendes
| Nom | Signification | Grade |
| Rendement en dividendes | 0 | 0 |
| DSI | 0 | 0 |
| Croissance moyenne du dividende | 0 | 0 |
Devoir
| Nom | Signification | Grade |
| Debt/EBITDA | -0.0277 | 10 |
| Debt/Ratio | 0.0099 | 10 |
| Debt/Equity | 0.5821 | 9 |
Impulsion de croissance
| Nom | Signification | Grade |
| Rentabilité Revenue, % | -98.5 | 0 |
| Rentabilité Ebitda, % | 260.68 | 10 |
| Rentabilité EPS, % | 72123839.39 | 10 |
paper.price.prices
| Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
| common.calendar.number_days.1 | 5.01 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.7d | 5.01 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.30d | 5.01 $ | 5.01 $ | 5.01 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.90d | 5.01 $ | 5.01 $ | 5.01 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.180d | 5.04 $ | 3.01 $ | 5.41 $ | -0.5952 % | 0 % | 0 % |
| common.calendar.number_days.1y | 8.27 $ | 0.2429 $ | 10.09 $ | -39.4 % | 0 % | 0 % |
| common.calendar.number_days.3y | 7.7 $ | 0.2429 $ | 10.09 $ | -34.94 % | 0 % | 0 % |
| common.calendar.number_days.5y | 0.2429 $ | 0.2429 $ | 14.73 $ | +2 062.58 % | 0 % | 0 % |
| common.calendar.number_days.10y | 0.2429 $ | 0.2429 $ | 14.73 $ | +2 062.58 % | 0 % | 0 % |
| common.calendar.number_days.ytd | 4.91 $ | 2.93 $ | 5.41 $ | +2.04 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
| Dr. Spyridon Papapetropoulos M.D., Ph.D. | CEO, President & Director | 510.37k | 1973 (52 année) |
| Mr. Timothy M. Cunningham CPA, M.B.A. | Chief Financial Officer | N/A | 1963 (62 année) |
| Dr. Julie Kerner Ph.D. | Senior Vice President of Business Operations | N/A | |
| Ms. Elizabeth Doolin | Senior Vice President of Clinical Development | 1965 (60 années) | |
| Dr. Mark A. Smith M.D., Ph.D. | Chief Medical Officer | 1955 (70 années) |
Informations sur l'entreprise
Adresse: Australia, Eastwood, 200 Greenhill Road - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.bionomics.com.au
Site web: https://www.bionomics.com.au
